{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T15:21:10Z","timestamp":1786116070247,"version":"build-2736575974"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T00:00:00Z","timestamp":1785974400000},"content-version":"vor","delay-in-days":35,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Beijing Natural Science Foundation","award":["7254468"],"award-info":[{"award-number":["7254468"]}]},{"name":"National Key Research and Development Program, China","award":["2023YFC2306902, 2023YFC2306900"],"award-info":[{"award-number":["2023YFC2306902, 2023YFC2306900"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-026-16474-5","type":"journal-article","created":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T14:56:23Z","timestamp":1783004183000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Beyond side effects: treatment-related adverse events are associated with improved survival outcomes in HCC patients on atezolizumab-bevacizumab therapy"],"prefix":"10.1186","volume":"26","author":[{"given":"Xiao-Qian","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Ming","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Chen","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"You","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji-Dong","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"You-Wen","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2586-1443","authenticated-orcid":false,"given":"Yuan-Yuan","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,2]]},"reference":[{"issue":"4","key":"16474_CR1","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1016\/j.jhep.2021.11.030","volume":"76","author":"AL Cheng","year":"2022","unstructured":"Cheng AL, Qin S, Ikeda M, et al. Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. J Hepatol. 2022;76(4):862\u201373.","journal-title":"J Hepatol"},{"issue":"20","key":"16474_CR2","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","volume":"382","author":"RS Finn","year":"2020","unstructured":"Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N Engl J Med. 2020;382(20):1894\u2013905.","journal-title":"N Engl J Med"},{"issue":"7","key":"16474_CR3","doi-asserted-by":"publisher","first-page":"7772","DOI":"10.1002\/cam4.5535","volume":"12","author":"T Tada","year":"2023","unstructured":"Tada T, Kumada T, Hiraoka A, et al. Adverse events as potential predictive factors of therapeutic activity in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab. Cancer Med. 2023;12(7):7772\u201383.","journal-title":"Cancer Med"},{"issue":"2","key":"16474_CR4","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1007\/s10637-023-01349-4","volume":"41","author":"S Takaki","year":"2023","unstructured":"Takaki S, Kurosaki M, Mori N, et al. Effects on survival of the adverse event of atezolizumab plus bevacizumab for hepatocellular carcinoma: a multicenter study by the Japan Red Cross Liver Study Group. Invest New Drugs. 2023;41(2):340\u20139.","journal-title":"Invest New Drugs"},{"key":"16474_CR5","doi-asserted-by":"crossref","unstructured":"Imai K, Takai K, Aiba M et al. Adverse Events in Targeted Therapy for Unresectable Hepatocellular Carcinoma Predict Clinical Outcomes. Cancers (Basel). 2024;16(18):3150.","DOI":"10.3390\/cancers16183150"},{"issue":"4","key":"16474_CR6","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1159\/000535839","volume":"13","author":"H Nam","year":"2024","unstructured":"Nam H, Lee J, Han JW, et al. Analysis of Immune-Related Adverse Events of Atezolizumab and Bevacizumab in Patients with Hepatocellular Carcinoma: A Multicentre Cohort Study. Liver Cancer. 2024;13(4):413\u201325.","journal-title":"Liver Cancer"},{"issue":"4","key":"16474_CR7","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1007\/s11523-024-01061-0","volume":"19","author":"M Persano","year":"2024","unstructured":"Persano M, Rimini M, Tada T, et al. Adverse Events as Potential Predictive Factors of Activity in Patients with Advanced HCC Treated with Atezolizumab Plus Bevacizumab. Target Oncol. 2024;19(4):645\u201359.","journal-title":"Target Oncol"},{"key":"16474_CR8","doi-asserted-by":"crossref","unstructured":"Shimose S, Iwamoto H, Tanaka M et al. Association between Adverse Events and Prognosis in Patients with Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab: A Multicenter Retrospective Study. Cancers (Basel). 2022;14(17):4284.","DOI":"10.3390\/cancers14174284"},{"issue":"11","key":"16474_CR9","doi-asserted-by":"publisher","first-page":"101190","DOI":"10.1016\/j.jhepr.2024.101190","volume":"6","author":"C Campani","year":"2024","unstructured":"Campani C, Pallas D, Sidali S, et al. Heterogeneity in adverse events related to atezolizumab-bevacizumab for hepatocellular carcinoma reported in real-world studies. JHEP Rep. 2024;6(11):101190.","journal-title":"JHEP Rep"},{"issue":"6","key":"16474_CR10","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1016\/S1470-2045(20)30156-X","volume":"21","author":"MS Lee","year":"2020","unstructured":"Lee MS, Ryoo BY, Hsu CH, et al. Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study. Lancet Oncol. 2020;21(6):808\u201320.","journal-title":"Lancet Oncol"},{"issue":"1","key":"16474_CR11","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1159\/000531182","volume":"13","author":"YS Song","year":"2024","unstructured":"Song YS, Yang H, Kang B, et al. Thyroid Dysfunction after Atezolizumab and Bevacizumab Is Associated with Favorable Outcomes in Hepatocellular Carcinoma. Liver Cancer. 2024;13(1):89\u201398.","journal-title":"Liver Cancer"},{"key":"16474_CR12","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.crimmu.2022.05.003","volume":"3","author":"L Lu","year":"2022","unstructured":"Lu L, Zhan M, Li XY, et al. Clinically approved combination immunotherapy: Current status, limitations, and future perspective. Curr Res Immunol. 2022;3:118\u201327.","journal-title":"Curr Res Immunol"},{"issue":"5","key":"16474_CR13","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1038\/nrclinonc.2011.30","volume":"8","author":"AX Zhu","year":"2011","unstructured":"Zhu AX, Duda DG, Sahani DV, Jain RK. HCC and angiogenesis: possible targets and future directions. Nat Rev Clin Oncol. 2011;8(5):292\u2013301.","journal-title":"Nat Rev Clin Oncol"},{"issue":"2","key":"16474_CR14","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1159\/000505189","volume":"9","author":"M Kudo","year":"2020","unstructured":"Kudo M. A New Era in Systemic Therapy for Hepatocellular Carcinoma: Atezolizumab plus Bevacizumab Combination Therapy. Liver Cancer. 2020;9(2):119\u201337.","journal-title":"Liver Cancer"},{"issue":"3","key":"16474_CR15","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1158\/1078-0432.CCR-18-1254","volume":"25","author":"MA Morse","year":"2019","unstructured":"Morse MA, Sun W, Kim R, et al. The Role of Angiogenesis in Hepatocellular Carcinoma. Clin Cancer Res. 2019;25(3):912\u201320.","journal-title":"Clin Cancer Res"},{"issue":"8","key":"16474_CR16","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1038\/s41591-022-01868-2","volume":"28","author":"AX Zhu","year":"2022","unstructured":"Zhu AX, Abbas AR, de Galarreta MR, et al. Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma. Nat Med. 2022;28(8):1599\u2013611.","journal-title":"Nat Med"},{"key":"16474_CR17","doi-asserted-by":"publisher","first-page":"175883592110311","DOI":"10.1177\/17588359211031141","volume":"13","author":"C Hsu","year":"2021","unstructured":"Hsu C, Rimassa L, Sun HC, Vogel A, Kaseb AO. Immunotherapy in hepatocellular carcinoma: evaluation and management of adverse events associated with atezolizumab plus bevacizumab. Ther Adv Med Oncol. 2021;13:17588359211031141.","journal-title":"Ther Adv Med Oncol"},{"issue":"4","key":"16474_CR18","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1159\/000535501","volume":"13","author":"M Kudo","year":"2024","unstructured":"Kudo M, Tsuchiya K, Shao YY, et al. Impact of Bevacizumab Being Skipped due to Adverse Events of Special Interest for Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab: An Exploratory Analysis of the Phase III IMbrave150 Study. Liver Cancer. 2024;13(4):401\u201312.","journal-title":"Liver Cancer"},{"key":"16474_CR19","doi-asserted-by":"crossref","unstructured":"Tokunaga T, Tateyama M, Kondo Y et al. Therapeutic Modifications without Discontinuation of Atezolizumab Plus Bevacizumab Therapy Are Associated with Favorable Overall Survival and Time to Progression in Patients with Unresectable Hepatocellular Carcinoma. Cancers (Basel). 2023;15(5):1568.","DOI":"10.3390\/cancers15051568"},{"issue":"5","key":"16474_CR20","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1016\/j.jceh.2019.07.012","volume":"9","author":"I Doycheva","year":"2019","unstructured":"Doycheva I, Thuluvath PJ. Systemic Therapy for Advanced Hepatocellular Carcinoma: An Update of a Rapidly Evolving Field. J Clin Exp Hepatol. 2019;9(5):588\u201396.","journal-title":"J Clin Exp Hepatol"},{"issue":"2","key":"16474_CR21","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1080\/07357907.2021.1994586","volume":"40","author":"T Yamamoto","year":"2022","unstructured":"Yamamoto T, Ito T, Hase T, et al. Immune-related Liver Injury is a Poor Prognostic Factor in Patients with Nonsmall Cell Lung Cancer Treated with Immune Checkpoint Inhibitors. Cancer Invest. 2022;40(2):189\u201398.","journal-title":"Cancer Invest"},{"issue":"19","key":"16474_CR22","doi-asserted-by":"publisher","first-page":"7052","DOI":"10.1002\/cam4.3378","volume":"9","author":"SL Chan","year":"2020","unstructured":"Chan SL, Yip TC, Wong VW, et al. Pattern and impact of hepatic adverse events encountered during immune checkpoint inhibitors - A territory-wide cohort study. Cancer Med. 2020;9(19):7052\u201361.","journal-title":"Cancer Med"},{"issue":"suppl4","key":"16474_CR23","doi-asserted-by":"publisher","first-page":"iv119","DOI":"10.1093\/annonc\/mdx225","volume":"28","author":"J Haanen","year":"2017","unstructured":"Haanen J, Carbonnel F, Robert C, et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(suppl4):iv119\u201342.","journal-title":"Ann Oncol"},{"key":"16474_CR24","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.ejca.2015.11.016","volume":"54","author":"JM Michot","year":"2016","unstructured":"Michot JM, Bigenwald C, Champiat S, et al. Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer. 2016;54:139\u201348.","journal-title":"Eur J Cancer"},{"issue":"12","key":"16474_CR25","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1111\/hepr.13824","volume":"52","author":"M Rimini","year":"2022","unstructured":"Rimini M, Kang W, Burgio V, et al. Validation of the easy-to-use lenvatinib prognostic index to predict prognosis in advanced hepatocellular carcinoma patients treated with lenvatinib. Hepatol Res. 2022;52(12):1050\u20139.","journal-title":"Hepatol Res"},{"issue":"5","key":"16474_CR26","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1159\/000528818","volume":"101","author":"M Persano","year":"2023","unstructured":"Persano M, Rimini M, Tada T, et al. Role of the Prognostic Nutritional Index in Predicting Survival in Advanced Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab. Oncology. 2023;101(5):283\u201391.","journal-title":"Oncology"},{"issue":"10","key":"16474_CR27","doi-asserted-by":"publisher","first-page":"7565","DOI":"10.1007\/s00432-023-04678-2","volume":"149","author":"M Rimini","year":"2023","unstructured":"Rimini M, Persano M, Tada T, et al. Survival outcomes from atezolizumab plus bevacizumab versus Lenvatinib in Child Pugh B unresectable hepatocellular carcinoma patients. J Cancer Res Clin Oncol. 2023;149(10):7565\u201377.","journal-title":"J Cancer Res Clin Oncol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-16474-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16474-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16474-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T07:37:05Z","timestamp":1786001825000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-16474-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,2]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["16474"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-16474-5","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,2]]},"assertion":[{"value":"3 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This is a secondary analysis based on IMbrave 150 study and GO30140 trial. The Data Use Agreement with Research Plan is approved by the Vivli platform (\n                      \n                      ). Both trials were conducted in accordance with the International Conference on Harmonization guidelines for Good Clinical Practice and the principles of the Declaration of Helsinki. The study protocols were reviewed and approved by ethics committees at each of the participating sites. The full lists of participating sites and ethics committees can be found at\n                      \n                      and\n                      \n                      . All patients gave written informed consent for participation.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"937"}}